AC
CORT icon

Aristeia Capital’s Corcept Therapeutics CORT Stock Holding History

Aristeia Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-501,558
Closed -$10.9M – 278
2023
Q1 		$10.9M Buy
+501,558
New +$11M 0.25% 96

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Aristeia Capital's CORT Position: Q2 2023 in Review

Aristeia Capital sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 501,558 shares — an estimated $10.9M sold.

Aristeia Capital first reported a position in CORT in Q1 2023 and held it in 1 quarter. The position peaked at $10.9M in Q1 2023. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

  • Aristeia Capital reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Aristeia Capital sold 501,558 Corcept Therapeutics shares in Q2 2023, an estimated $10.9M.
  • Aristeia Capital first reported a position in Corcept Therapeutics in Q1 2023 and held it in 1 quarter.
  • Aristeia Capital's Corcept Therapeutics position peaked at $10.9M in Q1 2023.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Aristeia Capital's 13F filing for Q2 2023, filed 14 Aug 2023.